These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 9694154)
1. Efficient ex vivo inhibition of perforin and Fas ligand expression by chimeric tRNA-hammerhead ribozymes. Du Z; Ricordi C; Inverardi L; Podack E; Pastori RL Hum Gene Ther; 1998 Jul; 9(11):1551-60. PubMed ID: 9694154 [TBL] [Abstract][Full Text] [Related]
2. A hammerhead ribozyme that cleaves perforin and fas-ligand RNAs in vitro. Du Z; Ricordi C; Podack E; Pastori RL Biochem Biophys Res Commun; 1996 Sep; 226(3):595-600. PubMed ID: 8831663 [TBL] [Abstract][Full Text] [Related]
3. [Experimental study of inhibiting CTLL-2 cell apoptosis and enhancing cytotoxicity to Yac-1 cell by hammerhead ribozyme]. Zhang M; Liu F; You Y; He W; Zou P; Chen ZC; Liu ZP; Liu LB Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):705-8. PubMed ID: 15730709 [TBL] [Abstract][Full Text] [Related]
4. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345 [TBL] [Abstract][Full Text] [Related]
5. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373 [TBL] [Abstract][Full Text] [Related]
6. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). Winter H; Hu HM; Urba WJ; Fox BA J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388 [TBL] [Abstract][Full Text] [Related]
7. [Blocking the escape of leukemic cells from killing of T cell by combining anti-Fas ribozyme and CD80-IgG fusion protein]. Liu LB; Li WM; He W; Zhang M; Xiao J; Zhong ZD; Li L; Zou P Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3469-74. PubMed ID: 16686062 [TBL] [Abstract][Full Text] [Related]
8. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307 [TBL] [Abstract][Full Text] [Related]
9. T-cell cytotoxicity of human Schwann cells: TNFalpha promotes fasL-mediated apoptosis and IFN gamma perforin-mediated lysis. Bonetti B; Valdo P; Ossi G; De Toni L; Masotto B; Marconi S; Rizzuto N; Nardelli E; Moretto G Glia; 2003 Aug; 43(2):141-8. PubMed ID: 12838506 [TBL] [Abstract][Full Text] [Related]
10. Inhibiting apoptosis of CTLL-2 cells to enhance their GVL effects via anti-Fas ribozyme. Zhang M; Liu F; Liu LB; You Y; Chen ZC; Zou P Acta Biochim Biophys Sin (Shanghai); 2004 Aug; 36(8):559-65. PubMed ID: 15295649 [TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of hammerhead ribozymes against perforin and fas-ligand RNA. Du Z; Ricordi C; Podack E; Pastori RL Transplant Proc; 1997 Jun; 29(4):2224-5. PubMed ID: 9193603 [No Abstract] [Full Text] [Related]
12. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand. Miura Y; Thoburn CJ; Bright EC; Hess AD Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881 [TBL] [Abstract][Full Text] [Related]
13. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways. Benihoud K; Bonardelle D; Bobé P; Kiger N Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912 [TBL] [Abstract][Full Text] [Related]
14. Activities of tRNA-embedded dimeric minizymes. Kuwabara T; Warashina M; Nakayama A; Ohkawa J; Taira K Nucleic Acids Symp Ser; 1997; (37):307-8. PubMed ID: 9586122 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Fas-mediated apoptosis in mouse insulinoma betaTC-3 cells via an anti-Fas ribozyme. Klein D; Ricordi C; Pugliese A; Pastori RL Hum Gene Ther; 2000 May; 11(7):1033-45. PubMed ID: 10811232 [TBL] [Abstract][Full Text] [Related]
16. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements. Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121 [TBL] [Abstract][Full Text] [Related]
17. Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. Hadida F; Vieillard V; Mollet L; Clark-Lewis I; Baggiolini M; Debré P J Immunol; 1999 Aug; 163(3):1105-9. PubMed ID: 10415001 [TBL] [Abstract][Full Text] [Related]
18. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939 [TBL] [Abstract][Full Text] [Related]
19. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice. Li Q; Nakadai A; Takeda K; Kawada T Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847 [TBL] [Abstract][Full Text] [Related]
20. Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection. Rode M; Balkow S; Sobek V; Brehm R; Martin P; Kersten A; Dumrese T; Stehle T; Müllbacher A; Wallich R; Simon MM J Virol; 2004 Nov; 78(22):12395-405. PubMed ID: 15507626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]